Vasoconstriction is the narrowing of the resulting from contraction of the muscular wall of the vessels, in particular the large arteries and small arterioles. The process is the opposite of vasodilation, the widening of blood vessels. The process is particularly important in controlling hemorrhage and reducing acute blood loss. When blood vessels constrict, the flow of blood is restricted or decreased, thus retaining body heat or increasing vascular resistance. This makes the skin turn paler because less blood reaches the surface, reducing the radiation of heat. On a larger level, vasoconstriction is one mechanism by which the body regulates and maintains mean arterial pressure.
Medications causing vasoconstriction, also known as vasoconstrictors, are one type of medicine used to raise blood pressure. Generalized vasoconstriction usually results in an increase in systemic blood pressure, but it may also occur in specific tissues, causing a localized reduction in blood flow. The extent of vasoconstriction may be slight or severe depending on the substance or circumstance. Many vasoconstrictors also cause pupil dilation. Medications that cause vasoconstriction include: , , and . Severe vasoconstriction may result in symptoms of intermittent claudication.
However, the specific mechanisms for generating an increased intracellular concentration of calcium depends on the vasoconstrictor. Smooth muscle cells are capable of generating action potentials, but this mechanism is rarely utilized for contraction in the vasculature. Hormonal or pharmacokinetic components are more physiologically relevant. Two common stimuli for eliciting smooth muscle contraction are circulating epinephrine and activation of the sympathetic nervous system (through release of norepinephrine) that directly innervates the muscle. These compounds interact with cell surface adrenergic receptors. Such stimuli result in a signal transduction cascade that leads to increased intracellular calcium from the sarcoplasmic reticulum through IP3-mediated calcium release, as well as enhanced calcium entry across the sarcolemma through calcium channels. The rise in intracellular calcium complexes with calmodulin, which in turn activates myosin light-chain kinase. This enzyme is responsible for phosphorylation the light chain of myosin to stimulate cross-bridge cycling.
Once elevated, the intracellular calcium concentration is returned to its normal concentration through a variety of protein pumps and calcium exchangers located on the plasma membrane and sarcoplasmic reticulum. This reduction in calcium removes the stimulus necessary for contraction, allowing for a return to baseline.
Exposure to water causes vasoconstriction near the skin, which in turn causes water-immersion wrinkling.
The routes of administration vary. They may be both systemic and topical. For example, pseudoephedrine is taken orally and phenylephrine is topically applied to the nasal passages or eyes. Examples include:
For example, vasoconstriction is a hypothermic preventative in which the blood vessels constrict and blood must move at a higher pressure to actively prevent a hypoxic reaction. ATP is used as a form of energy to increase this pressure to heat the body. Once homeostasis is restored, the blood pressure and ATP production regulates. Vasoconstriction also occurs in superficial blood vessels of warm-blooded animals when their ambient environment is cold; this process diverts the flow of heated blood to the center of the animal, preventing the loss of heat.
↑Stretch-activated ion channels | depolarization -->
|
↓ATP-sensitive K+ channel | |
↑Ca2+ | |
NPY receptor | Activation of Gi --> ↓cAMP --> ↓PKA activity --> ↓phosphorylation of MLCK --> ↑MLCK activity --> ↑phosphorylation of MLC (calcium-independent) |
↑α1 adrenergic receptor | Activation of Gq --> ↑phospholipase C activity --> ↑IP3 and diacylglycerol --> activation of IP3 receptor in SR --> ↑intracellular Ca2+ |
↑thromboxane receptor | |
↑endothelin receptor ETA | |
↑Angiotensin receptor 1 |
|
open VDCCs --> ↑intracellular Ca2+ Page 771 | |
Reduced production of nitric oxide | |
Arginine vasopressin receptor 1 (V1) on smooth muscle cells | Activation of Gq --> ↑phospholipase C activity --> ↑IP3 and diacylglycerol --> activation of IP3 receptor in SR --> ↑intracellular Ca2+ |
Endothelin production | |
|
Improper vasoconstriction may also play a role in secondary hypertension.
To summarize, vasoconstriction is a physiological process that involves the narrowing of blood vessels, particularly arteries and arterioles, resulting in a reduction of blood flow to specific tissues or organs. This phenomenon is primarily regulated by the contraction of smooth muscle cells within the vessel walls. Several factors contribute to vasoconstriction, including the release of vasoconstrictor substances such as endothelin and angiotensin II, both of which play crucial roles in the modulation of vascular tone.
Additionally, sympathetic nervous system activation, triggered by stress or other stimuli, prompts the release of norepinephrine, a neurotransmitter that induces vasoconstriction by binding to alpha-adrenergic receptors on smooth muscle cells. The narrowing of blood vessels leads to an increase in peripheral resistance, thereby elevating blood pressure. While vasoconstriction is a normal and essential regulatory mechanism for maintaining blood pressure and redistributing blood flow during various physiological processes, its dysregulation can contribute to pathological conditions. Chronic vasoconstriction is associated with hypertension, a major risk factor for cardiovascular diseases such as heart attack and stroke. Moreover, impaired blood flow resulting from abnormal vasoconstriction may contribute to tissue ischemia, which can be observed in conditions like Raynaud's disease. Understanding the pathology of vasoconstriction is crucial for developing targeted therapeutic strategies to manage conditions associated with abnormal vascular tone.
|
|